期刊文献+

CK7,CEA,CA125,KI67基因在卵巢肿瘤手术盆腔冲洗液沉渣中的诊断与研究

The Diagnosis and Research of CK7,CEA,CA125 and KI67 Genes Combined with Sediment Immersion in Pelvic Rinses in Ovarian Tumor
下载PDF
导出
摘要 目的探讨盆腔冲洗液沉渣切片联合免疫组化检测CK7、CEA、CA125、Ki-67在卵巢肿瘤诊断中的临床意义。方法收集2014年1月~2016年12月我院卵巢肿瘤患者手术中的盆腔冲洗液72例,进行盆腔冲洗液沉渣包埋,沉渣包埋后切片行HE染色和CK7、CEA、CA125、Ki-67的免疫组织化学染色。结果沉渣包埋切片HE染色观察,上皮性恶性肿瘤检出率为44.4%(32/72)。以沉渣包埋组织HE切片诊断检出结果为标准进行分组,分为上皮性卵巢恶性肿瘤组(32例)和非恶性肿瘤组(40例),计算各组免疫组化标记物的表达情况。卡方检验显示,各组间CK7、CA125和ki-67的阳性表达率具有显著性差异(P<0.01),CEA表达无显著差异(P>0.05)。结论盆腔冲洗液沉渣包埋组织石蜡切片联合免疫组化检测CK7、CEA、CA125、Ki-67可以协助诊断卵巢恶性肿瘤,并为明确恶性肿瘤细胞组织来源提供了客观依据。 Objective To investigate the diagnostic value of sediment immersion in pelvic rinsesand immunhistochemical detection of CK7、CEA、CA125and Ki67in ovarian tumor.Methods72cases of sediment immersion in pelvic rinses of ovarian tumor were collected,embededed,siliced forimmunohistochemical detection of CK7,CEA,CA125and Ki67.Results The positive expression ofCK7,CA125and ki-67in ovarian malignant tumor was higher than that in ovarian tumor(P<0.01),butunrelated with CEA(P>0.05).Conclusion Sediment immersion in pelvic rinses and immunhistochemical detection of CK7、CEA、CA125and Ki67in ovarian tumor can help to diagnosis the ovarian malignant tumor.
作者 谭丽珊 陈智慧 余健华 陈玉英 郭慧 TAN Li-shan;CHEN Zhi-hui;YU Jian-hua;CHEN Yu-ying;GUO Hui(Shaoguan First People's Hospital,Shaoguan 512000,China;Shaoguan College School of Medicine,Shaoguan 512000,China)
出处 《现代诊断与治疗》 CAS 2017年第15期2747-2749,共3页 Modern Diagnosis and Treatment
关键词 盆腔冲洗液沉渣 免疫组化 卵巢 诊断 Sediment Immersion in Pelvic Rinses Immunohistochemistry Ovarian Diagnosis
  • 相关文献

参考文献6

二级参考文献68

  • 1张健,李丽蟾,牛建梅.经阴道超声估计盆腔积液量的计算方法探讨[J].上海医学,2005,28(12):1048-1049. 被引量:3
  • 2张晶.妇产科超声检查指南及报告书写示范[J].中国超声医学杂志,2007,23(3):238-240. 被引量:10
  • 3魏峥跃.超声在女性盆腔积液鉴别诊断中的临床价值[J].中国民康医学,2007,19(13):549-549. 被引量:3
  • 4杨开选,孙亮,徐炼,万宇,宋波,姚先莹.24例卵巢异位子宫内膜恶变的临床病理分析及恶变机理[J].现代预防医学,2007,34(14):2790-2791. 被引量:9
  • 5Kadri Altundag, Ozden Altundag, Paolo Morandi, et al. CA125 Nadir Values As Prognostic Factor in Epithelial Ovarian Cancer [J]. J.Clin. Oncol,2005,23:2435-2436.
  • 6Oliver Dorigo and Jonathan S, Berek. Personalizing CA125 Levels for Ovarian Cancer Screening [J]. Cancer Prevention Research,2011,4: 1356-1359.
  • 7Jung Ha Shin, Jeong Hoon Bae, Ahwon Lee, et al. CK7,CK20,CDX2and MUC2 Immunohistochemical Staining Used To Distinguish Metastatic Colorectal Carcinoma Involving Ovary from Primary Ovarian Mucinous Adenocarcinoma [J]. J. Clin. Oncol,2010,40:208 - 213.
  • 8Anna H.Woodard, Jing Yu, David J.Dabbs, et al. NY-BR-I and PAX8 Immunoreactivity in Breast,Gynecologic Tract, and Other CK7+ Carcinomas: Potential Use for Determining Site of Origin [J]. Am J Clin Pathol,2011,136:428-435.
  • 9Marion T Weigel and Mitch Dowsett. Current and emerging biomarkers in breast cancer: prognosis and prediction [J]. Cancer, 2010,17:245 -262.
  • 10Cynthia Kuk, Vathany Kulasingam, C.Geeth Gunawardana, et al. Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers[J]. Mol.Cell.Proteomics,2009,8:661-669.

共引文献209

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部